Egetis Therapeutics AB (publ) (STO:EGTX)

Egetis Therapeutics AB Revenue

Egetis Therapeutics AB had revenue of 17.40M SEK in the quarter ending June 30, 2026, with 20.00% growth. This brings the company's total for the last twelve months to 66.00M, up 39.24% year-over-year. In the year 2025, Egetis Therapeutics AB had annual revenue of 62.40M with 35.36% growth. That makes Egetis Therapeutics AB the 38,984th largest company in the world by revenue and 537th in Sweden.

• Revenue (ttm): 66.00M
• Revenue Growth: +39.24%
• P/S Ratio: 70.87
• Revenue / Employee: 1.18M
• Employees: 56
• Market Cap: 4.68B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Emcitate 62.30M 99.8%
• Aladote 100.00K 0.2%

By Geography

Chart

• Europe (excluding Sweden) 61.50M 98.6%
• Sweden 500.00K 0.8%
• Rest of the World 400.00K 0.6%

Fiscal year ended Dec 31, 2025 See the full Egetis Therapeutics AB breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	62.40M	16.30M	35.36%
Dec 31, 2024	46.10M	-11.50M	-19.97%
Dec 31, 2023	57.60M	35.00M	154.87%
Dec 31, 2022	22.60M	-15.60M	-40.84%
Dec 31, 2021	38.20M	-2.46M	-6.05%
Dec 31, 2020	40.66M	-41.90M	-50.75%
Dec 31, 2019	82.56M	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue segment and geography data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error